[go: up one dir, main page]

WO2015032981A1 - Conjugués d'érythropoïétine présentant une biodisponibilité orale - Google Patents

Conjugués d'érythropoïétine présentant une biodisponibilité orale Download PDF

Info

Publication number
WO2015032981A1
WO2015032981A1 PCT/EP2014/069198 EP2014069198W WO2015032981A1 WO 2015032981 A1 WO2015032981 A1 WO 2015032981A1 EP 2014069198 W EP2014069198 W EP 2014069198W WO 2015032981 A1 WO2015032981 A1 WO 2015032981A1
Authority
WO
WIPO (PCT)
Prior art keywords
epo
conjugate according
group
epo conjugate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2014/069198
Other languages
English (en)
Inventor
Mateja Cegnar
Barbara Podobnik
Vladka Gaberc Porekar
Mateja Novak Stagoj
Spela JALEN
Radovan Komel
Simon CASERMAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals dd filed Critical Lek Pharmaceuticals dd
Publication of WO2015032981A1 publication Critical patent/WO2015032981A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • the present invention relates to erythropoietin (EPO) conjugates having a high bioavailability and efficacy, especially when administered perorally. Also provided are methods for preparing the EPO conjugates, their use for treating various diseases, and pharmaceutical compositions comprising said EPO conjugates, alone or in combination with absorption enhancers and/or coating polymers.
  • EPO erythropoietin
  • EPO increases hemoglobin serum levels thus reducing the need for blood transfusion. It is used in the treatment of anemia, for example resulting from chronic kidney disease and
  • myelodysplasia from cancer therapy (for example chemotherapy and/or radiation), as well as from other critical illnesses (for example heart failure).
  • cancer therapy for example chemotherapy and/or radiation
  • other critical illnesses for example heart failure
  • EPO Due to its low bioavailability after oral administration, the use of EPO is limited to invasive, parenteral administration. Therefore, there are currently no oral formulations of EPO available. Major constraints in this regard are the poor absorption as well as the rapid and extensive degradation of EPO in the gastrointestinal tract. The poor absorption is mostly due to EPO's large molecular size and low lipophilicity, which limits its permeability across the intestinal epithelium.
  • EPO can be produced biosynthetically using recombinant DNA technology.
  • the recombinant human EPO (rhEPO) dosage form currently available on the market is a ready for injection liquid vial (syringe), which is usually administered 2-3 times weekly.
  • rhEPO recombinant human EPO
  • cumulative doses are required that significantly exceed levels of endogenous EPO.
  • serum levels result in prolonged circulation times of EPO and unspecific binding to non-targeted tissue, which may lead to undesired side effects.
  • severe side effects have been recently reported in chemotherapy and/or radiation receiving cancer patients taking anti-anemia drugs.
  • the peroral route would be the most convenient. It is also contemplated that the peroral delivery of EPO would benefit from entering the systemic circulation via the portal vein, which would more closely resemble the physiological pathway of endogenous EPO that is produced in the liver.
  • US 2006/01 1 1279 provides conjugates of EPO with polyethylene glycol (PEG) moieties.
  • the conjugates are linked via an intact glycosyl linking group interposed between, and covalently attached to the peptide and the modifying group.
  • the conjugates are formed from glycosylated peptides by the action of a glycosyltransferase.
  • an EPO-PEG derivative was intravenously administered into rats and compared with non-pegylated EPO.
  • the pegylated EPO showed a longer distribution time in the circulation than the non pegylated EPO.
  • a longer circulation time may be indicative for a lower biological activity, because circulating EPO is not present at the place of action.
  • the present invention overcomes the aforesaid problems by providing EPO conjugates having a high bioavailability and efficacy, which are suitable for oral administration.
  • the present invention provides novel modified EPO derivatives comprising one or more lipophilic side chains referred to herein as EPO conjugates. It has been surprisingly found that a better oral bioavailability of EPO can be achieved by this covalent modification of EPO. In addition to the high bioavailability after oral administration, the novel EPO conjugates also display high efficacy. Pharmaceutical compositions of the novel EPO conjugates are further provided herein, which involve the use of an absorption enhancer and/or a coating with a coating polymer. Both, conjugation and formulation with an absorption enhancer and/or a coating with a coating polymer are able to promote the permeability of the protein across the intestinal epithelia in a synergistic manner.
  • the types of conjugations provided by the present invention may also be applied to other therapeutic proteins, similarly resulting in increased bioavailability of these therapeutic proteins after peroral administration.
  • These other therapeutic proteins include, but are not limited to, Granulocyte colony- stimulating factor (G-CSF), Granulocyte macrophage colony-stimulating factor (GM-CSF), Insulin like Growth Factor (IGF), Interleukine 17, Interleukine 2, Interferon alpha, Interferon beta, Parathyroid hormone (PTH), Human Growth Hormone (HGH), Fibroblast growth factor (FGF), Relaxin, Salmon Calcitonin and Fab fragments.
  • G-CSF Granulocyte colony- stimulating factor
  • GM-CSF Granulocyte macrophage colony-stimulating factor
  • IGF Insulin like Growth Factor
  • IGF Insulin like Growth Factor
  • PTH Interleukine 17, Interleukine 2, Interferon alpha, Interferon beta
  • PTH Parathyroid hormone
  • HGH Human Growth Hormone
  • EPO refers to erythropoietin and may be a natural or recombinant EPO, recombinant human EPO (rhEPO), or any protein or peptide having in vivo biological activity of the EPO glycoprotein, e.g., a wild type or mutant EPO, an EPO peptidomimetic, or an EPO fragment.
  • the species from which EPO is derived can be animal, mammal or human species.
  • Human EPO is, however, preferred.
  • Human EPO comprises the known human erythropoietin having 165 amino acids after posttranslational cleavage of the N-terminal signal peptide of 27 amino acids and the C-terminal arginine. It further comprises human EPO in it's naturally glycosylated state, i.e., including all carbohydrate side chains.
  • P as used herein stands for EPO as defined above.
  • the invention provides novel EPO conjugates comprising EPO and one or more lipophilic side chain(s).
  • the one or more lipophilic side chain(s) may be attached to the oamino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residues present on the EPO amino- acid sequence, e.g., via an amide bond.
  • the lipophilic side chain may be attached to the sugar components present in glycoproteins such as EPO.
  • Each of the one or more lipophilic side chain(s) attached to the EPO comprises one or more moieties "B” and/or a branched or straight chain alkylene moiety -(CH 2 ) m - ⁇ While each of the one or more lipophilic side chain(s) attached to the EPO may comprise up to 6 moieties "B", it is equally preferred that each of the one or more lipophilic side chain(s) attached to the EPO comprises only one moiety "B".
  • the moiety B is a bivalent aromatic moiety selected from arylene or heteroarylene.
  • arylene refers to a bivalent aromatic moiety comprising 4, 5, 6 or 7 ring carbon atoms.
  • heteroarylene refers to an arylene group comprising 1 , 2, 3 or 4 hetero-ring atoms each independently selected from oxygen, nitrogen, and sulfur.
  • the arylene or heteroarylene moiety may, each and independently, be unsubstituted, or may be substituted with one or two substituents each independently selected from straight chain or branched Ci_ 4 - alkyl, -OH, -SH, -NH 2 , -CHO, and -COOH.
  • the alkylene moiety -(CH 2 ) m - is branched or straight chain alkylene moiety having 4 to 20 carbon atoms, or from 5 to 1 1 carbon atoms, or having 5, 7, 9 or 1 1 carbon atoms (i.e., m is an integer from 4 to 20, or from 5 to 1 1 , or m is 5, 7, 9 or 1 1 ).
  • the lipophilic side chain(s) may further comprise a polar end group Y and/or one or more linker(s) each independently selected from the group consisting of L and X.
  • the linker X is selected from -CH 2 NH-, -NHCO-, -CONH-, -COO-, -SS-, -S-CH 2 - and -NN-;
  • the polar end group Y is a polar group selected from -COOH, -CHO and -COOCH 3 . While it is preferred that a polar group Y is present in the EPO conjugates of the invention, it is equally preferred that no polar group Y is present therein.
  • the number of lipophilic side chains attached to EPO ranges from 1 to 6, for example, 1 , 2, 3, 4, 5 or 6 side chains may be present in the EPO conjugates according to the invention. If more than one lipophilic side chains are present in the EPO conjugates of the invention, e.g., if 2 or more side chains are present, these lipophilic side chains may either be the same or different.
  • the one or more lipophilic side chain(s) attached to the EPO comprise(s) one or more of a bivalent aromatic moiety B, wherein B is arylene. Said arylene moiety may have 4, 5, 6 or 7 ring carbon atoms.
  • Said arylene moiety is either unsubstituted, or is substituted with one or two substituents each independently selected from -CH 3 , -OH, -SH, -NH 2 , -CHO, and -COOH.
  • the substituent -CH 3 is preferred.
  • B is a phenylene, toluylene, or xylene moiety. More preferably, B is an o-, m- or p-phenylene moiety, most preferably a p-phenylene moiety.
  • the one or more lipophilic side chain(s) attached to the EPO comprise(s) one or more of a bivalent aromatic moiety B and/or a branched or straight chain alkylene moiety -(CH 2 )m-, and further one or more linker(s) each independently selected from the group consisting of L and X, and/or a polar end group Y, wherein
  • L represents -NHCO-
  • n is an integer from 4 to 20, or from 5 to 1 1 , or is 5, 7, 9 or 1 1 ;
  • Y is selected from -COOH, -CHO, and -COOCH 3 ; preferably Y is -COOH.
  • EPO conjugates of the present invention are represented by the following formula
  • P EPO
  • B represents a hetero- or homo-bifunctional linker, enabling attachment of the lipophilic moiety to the protein.
  • B represents a bivalent aromatic moiety, preferably an arylene or heteroarylene moiety with 4, 5, 6 or 7 ring carbon atoms, more preferably 6 carbon atoms, and optionally, one oxygen, nitrogen, or sulfur ring atom, which arylene or heteroarylene group may be unsubstituted or substituted with one or two groups selected from straight chain or branched d-4-alkyl, -OH, -SH, -NH 2 , -CHO, -COOH.
  • a preferred substituent for the arylene or heteroarylene group is methyl.
  • B represents a phenylene, toluylene, xylene or pyridylene group. More preferably, B is an o-, m- or p-phenylene group, most preferably a p-phenylene group;
  • X represents a covalent linkage between B and the lipophilic moiety, wherein X is
  • X represents -CH 2 NH-, -NHCO-, or -CONH-, more preferably X represents -CH 2 NH-;
  • (CH 2 )m represents a branched or straight chain alkylene moiety having 4 to 20 carbon atoms, or from 5 to 1 1 carbon atoms, or having 5, 7, 9 or 1 1 carbon atoms (i.e., m is an integer from 4 to 20, or from 5 to 1 1 , or m is 5, 7, 9 or 1 1 );
  • Y represents a polar group selected from -COOH, -CHO, and -COOCH 3 .
  • Y is - COOH;
  • n represents the number of lipophilic side chains attached to EPO, preferably attached via an amide bond to the oamino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residues present on the EPO amino-acid sequence, n may be selected from 1 to 6.
  • n is 2 or 3.
  • the values for n equal to 2 or 3 are preferred in order to carry out the fine tuning of lipophilicity.
  • the EPO conjugate has the general formula
  • P EPO
  • L, B, X, m and Y are defined as in any one of the above embodiments, and
  • n represents the number of lipophilic side chains attached to EPO and ranges from 1 to 6.
  • the lipophilic side chain [(L)-B-(X)-(CH 2 ) m -Y] may be attached via an amide bond to the oamino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residues present on the EPO amino-acid sequence.
  • EPO conjugates are represented by the following formulas:
  • sequence of the structural elements according to any of the above formulas is preferred as allows an attachment of the one or more lipophilic side chain(s) to the oamino group of the N-terminal amino acid and/or to the ⁇ -amino group of lysine residue present on the EPO amino-acid sequence, e.g., via an amide bond , and via an aromatic moiety B to the linker X.
  • the partial group -(CH 2 ) m -Y can be introduced, e.g., by a ⁇ -amino carboxylic acid.
  • the lipophilic side chains comprise the structural elements in the order given in the above formulas
  • the parameters as defined above i.e., L, B, X, -(CH 2 ) m -, n and Y
  • L, B, X, -(CH 2 ) m -, n and Y are to be understood in that they are independent of each other and can be selected and combined freely. If they occur repeatedly within one molecule, for example in the case that more than one side chains are present per molecule erythropoietin, e.g., if n is 2 or more, the parameters may be different in each side chain.
  • the bivalent linker parameters L, B and X may be present in the orientation as depicted in the above formulas, but also in reversed orientation.
  • the lipophilic side chain(s) of the EPO conjugates as defined above typically comprises one bivalent aromatic moiety B.
  • more than one bivalent aromatic moieties B may be present as well, e.g., 2, 3, 4, 5 or 6 bivalent aromatic moieties B may be present.
  • the covalent linkage(s) L and/or X in the lipophilic side chain of the EPO conjugate as defined above may be present or omitted.
  • EPO erythropoietin
  • the term erythropoietin, or abbreviated EPO comprises any natural or recombinant EPO, recombinant human EPO (rhEPO), or any protein or peptide having in vivo biological activity of EPO glycoprotein, i.e. wild type or mutant EPO, EPO peptidomimetic, or EPO fragment.
  • the species from which the EPO is derived comprise animal, mammal or human species, especially human EPO.
  • Human EPO comprises the known human erythropoietin having 165 amino acids after posttranslational cleavage of the N-terminal signal peptide of 27 amino acids and the C-terminal arginine. It may further comprise the human erythropoietin in the naturally glycosylated state, i.e. including all carbohydrate side chains.
  • P is preferably a human recombinant EPO (rhEPO).
  • the EPO conjugates according to the present invention possess many advantages.
  • the novel EPO conjugates are more lipophilic, less susceptible to enzymatic degradation and retain the in vivo biological activity of native or endogenous EPO of causing bone marrow cells to increase the production of reticulocytes (red blood cell progenitors) and red blood cells.
  • the present EPO conjugates In comparison with unmodified EPO, the present EPO conjugates have an increased permeability across the intestinal membrane. Therefore, the present EPO conjugates are particularly suited for peroral administration and/or for the development of advanced oral drug delivery systems.
  • the oral administration of the EPO conjugates provided herein results in plasma concentrations of EPO, which are lower than after parenteral administration, but higher than in untreated patients.
  • the plasma concentrations of EPO achieved after oral administration of the EPO conjugates provided herein thus cause a therapeutic effect, but reduce the occurrence of side effects.
  • a further advantage of the EPO conjugates according to the present invention lays in its closer resemblance to endogenous EPO entering the systemic circulation via the portal vein.
  • Endogenous EPO is produced by the peritubular capillary endothelial cells in the kidney and liver.
  • the liver accounts for 10-20% of EPO production and the liver can naturally regulate EPO plasma levels.
  • Enteral absorption of EPO results in better regulation of hormone levels by feed back regulation mechanisms in the liver, thereby preventing peak concentrations of the drug that are responsible for the undesired side effects. This regulation is not efficient upon peripheral administration of EPO.
  • one of the benefits of the EPO conjugates of the invention is the reduction of severe side effects in comparison to parenterally administered EPO of the current commercial preparation.
  • EPO conjugates of the present invention can be administered orally, they achieve high patient compliance. Further, the production costs of peroral EPO formulations are reduced compared to the costs for producing parenteral EPO formulations. Absorption Enhancers / Nanocomplex formation
  • the invention further provides pharmaceutical compositions (formulations) comprising EPO, particularly the EPO conjugates of the invention, together with at least one absorption enhancer.
  • absorption enhancers are cycloalkylglycosides (cycloalkylmaltosides, "CYMALs"). These chemically synthesized molecules are composed of a sugar, typically a disaccharide.
  • the carbohydrate component is linked by an O-glycosidic bond at the "free end" of maltose (carbon atom number 1 ) to an alkyl chain, wherein the alkyl chain comprises at the most distal position of the alkyl chain, the so called ⁇ -position, a cycloalkyl group.
  • the preferred disaccharide is maltose; the preferred alkyl chain comprises 1 to 7 methylene groups, i.e. (CH 2 )i-7, and the cycloalkyl rest at the ⁇ -position is a cyclohexyl group.
  • Preferred "CYMALs” are CYMAL®-5, CYMAL®-6 and CYMAL®-7,
  • a further group of preferred absorption enhancers are amphiphilic polymers referred to herein as "PMALs" having a highly charged cationic and anionic backbone to which an aliphatic tail is attached.
  • the expression “PMAL” describes alternant polymers prepared by the monomers maleic acid anhydride and an oolefine having 6, 8, 10, 12, 14, 16 or 18 carbon atoms, respectively (i.e., "poly(maleic acid anhydride-alt-oolefine"), which are grafted with
  • dimethylamino propylamine side chains may be prepared by reaction of poly(maleic acid anhydride-alt-oolefine with 3-dimethylamino propylamine, whereby the anhydride group reacts with the primary amino function of the 3-dimethylamino propylamine to form an amide bond.
  • the "non-reacting" or leaving carboxylic acid function of the original anhydride function is present as a free carboxylic acid, and simultaneously, the basic dimethylamino function is present in the side chain.
  • a zwitterionic or ampholytic polymer (“amphipol") is obtained.
  • PMALs can form organized assemblies ("nanocomplexes") with EPO or its conjugates. The advantage is that upon administration of these nanocomplexes, only the absorption of the EPO molecule (protein) complexed to PMAL is promoted.
  • Amphipols have been described in protein technology processes to solubilize membrane proteins and to improve their solubility in water (Gorzelle BM et al.,. J Am Chem Soc 124, 2002). However, they have never been used as absorption promoting agents as provided herein.
  • the size of the nanocomplexes formed by the EPO conjugates of the invention and the at least one absorption enhancer(s) as defined above ranges between 6 and 30 nm.
  • the present invention further provides coated pharmaceutical compositions comprising comprising EPO, particularly the EPO conjugates of the invention, alone or in combination with at least one absorption enhancer as provided herein, which are coated with one or more coating polymer(s).
  • coated pharmaceutical compositions is interchangeably used herein with the term “nanoparticle compositions” or “nanoparticles”.
  • the one or more, e.g., one or two, coating polymer(s) may be coating polymer(s) selected from the group of natural or synthetic hydrophilic polymers such as polymers based on polyacrylic acid (Carbopol®, Carbomer®); polyanhydrides such as polymethyl vinyl ether/maleic anhydrides; enteric polymers such as Eudragit®, basic and acidic polysaccharides such as chitosan and its derivatives, alginic acid or its salts, pectin, hyaluronic acid, tragacanth; and polyesters such as copolymers of lactic/glycolic acids with amino acids.
  • polyacrylic acid Carbopol®, Carbomer®
  • polyanhydrides such as polymethyl vinyl ether/maleic anhydrides
  • enteric polymers such as Eudragit®, basic and acidic polysaccharides such as chitosan and its derivatives, alginic acid or its salts, pectin, h
  • the preferred polymers of the present invention include cationic natural polymers such as chitosan and its derivatives such as trimethylchitosan, and anionic polysaccharides such as alginic acid or its salts. These polymers have the advantage that they are generally non-toxic and not irritating to the mucosa, and do not require organic solvents, which would not be desirable from the point of protein stability and additionally adversely affect the patient.
  • the chitosan derivate trimethylchitosan may function as both, an absorption promoting agent and as part of the polymer coating.
  • one or more additional absorption enhancing agent e.g., as defined above
  • the polymers are added to form nanoparticles providing partial protection against protein degradation, and mucoadhesivness to localize the delivery system closer to the intestinal wall.
  • a method for nanoparticle formation is based on self association of the ingredients in aqueous media under mild stirring conditions. Further formation of nanoparticles can be obtained by ionotropic gelation or polyelectrolyte complexation using counter ions, for example
  • Tripolyphosphate is a particularly suitable counterion in this regard. This process does not require the use of organic solvents, toxic ingredients or crosslinking agent and also does not employ harsh processing conditions necessary for the nanoparticle formation, therefore, the biological activity of the sensitive protein drug is preserved. The method also does not face technical and economical hurdles, therefore it is suitable for industrial scale production.
  • the size of the nanoparticles in the coated pharmaceutical compositions ranges between 200- 400 nm.
  • the size of the nanoparticles should not exceed a certain threshold.
  • the nanoparticle size should be less than 4000 nanometers, preferably less than 1000 nanometers, more preferably less than 500 nanometers, and most preferably less than 400 nanometers. Nanoparticles from 300 to 400 nanometers are particularly preferred.
  • the present invention further provides a process for the production of the EPO conjugates according to the present invention.
  • General preparation method
  • the process for the preparation of the EPO conjugates, wherein the one or more lipophilic side chain(s) are attached to 1 to 6 oamino group(s) of the N-terminal amino acid and/or to the ⁇ -amino group(s) of lysine residue present on the EPO provided herein generally comprises four steps: (1 ) modification (conversion) of a primary amine of the EPO into an amid linker and simultaneous introduction of an aldehyde group, (2) conjugation to an amino fatty acid and reductive amination, (3) gel filtration, (4) concentration and sterile filtration.
  • the first reaction step involves protein modification, wherein one or more bifunctional linker moieties B are attached to 1 to 6 oamino group(s) of the N-terminal amino acid and/or to the ⁇ -amino group(s) of lysine residues present on the EPO amino-acid sequence via reaction of EPO with a reagent comprising the aromatic moiety B substituted with an N-hydroxysuccinimidyl ester functional group (also referred to as NHS activated ester of B), and an aldehyde functional group.
  • B has the same meaning as defined in any of the above embodiments.
  • the N- hydroxysuccinimidyl ester reacts in an acylation reaction with the amino group of the EPO in that the N-hydroxysuccinimide serves as leaving group and the carbonyl group of the former NHS ester forms an amide bond with the amino group of the protein.
  • the intermediate product of this step can be formulated as:
  • the aromatic moiety B is a phenylene moiety.
  • the specific reagent employed in this reaction step is N-hydroxysuccinimidyl 4-formylbenzoate (SFB).
  • the respective reagent may be used in equimolar amounts, it is preferred that the reagent is used in excess amounts over EPO.
  • the molar excess ratio of SFB/EPO is from 6 to 36.
  • Preferably 6 molecules SFB per molecule EPO are used.
  • the aldehyde function is condensed with the amino function of a ⁇ -amino carboxylic acid to the corresponding Schiff's base.
  • the ⁇ -amino carboxylic acids may comprise 4 to 20 methylene groups: HOOC-(CH 2 )4-2o-NH 2 , preferably from 4 to 12 methylene groups.
  • the ⁇ -amino carboxylic acid may be used in equimolar amounts, it is preferred that the ⁇ -amino carboxylic acid is used in excess amounts over EPO.
  • the molar excess ratio of SFB/EPO may be from 30 to 120, or from 30 to 90.
  • 60 molecules of ⁇ -amino carboxylic acid per molecule EPO are used.
  • the intermediate product of this step can be formulated as:
  • a reducing agent known to the skilled artisan.
  • complex alkali borohydrides such as sodium cyanoborohydride (Na[CN-BH 3 ]) may be used.
  • the final product can be formulated as:
  • the Schiff base intermediate may be isolated before performing the reduction step. It is, however, not necessary to isolate the Schiff base intermediate. Rather, the Schiff base intermediate can be processed further directly into the final product (i.e., reduction to the final EPO conjugate as defined above). Hence, the condensation and reducing reactions can be effected in a "one pot" manner.
  • the final reaction mixture can be purified by separating by-products, such as non-reacted EPO, e.g., rhEPO, or excess reagents such as SFB and ⁇ -aminocarboxylic acid, from the desired conjugated EPO product.
  • Suitable purification techniques are known to one skilled in the art, such as column chromatography, or size exclusion chromatography with a gel ("gel filtration").
  • a Superdex75 PrepGrade (XK 26/60) column from Sigma/Aldrich may be used for purification by gel filtration.
  • the fractions containing the desired conjugated EPO can be collected, concentrated, for example by ultrafiltration, and filtrated with a sterile filter into a sterile state.
  • the one or more lipophilic side chains may be attached to the sugar components present on the glycoprotein EPO.
  • the sugar components can be modified so as to obtain aldehyde reactive groups. Oxidation with sodium periodate can be used for converting a relatively non-reactive sugar hydroxyl groups into the aldehyde groups (oxidation). Modification of the specific sugar components takes place in a periodate concentration-dependent manner. Sodium periodate in low concentrations (1 mM) specifically converts sialic acids. At a higher concentration of periodate (10 mM, and more), CC bond cleavage between the two cis-hydroxyl groups on sugar units occurs in addition to oxidation of terminal sialic groups.
  • terminal sialic acids are the most prone groups for modification.
  • the oxidation of sugar moieties yielding free aldehyde groups available for modification could be achieved through enzymatic reactions (e.g. glucose oxidase as described in Biotechnol Appl Biochem. 1994, (Pt1 ): 45-53).
  • the resulting aldehyde group can be reacted with primary or secondary amines in the next step, thus leading to the formation of unstable Schiff bases.
  • These intermediates are after reduction (e.g., with NaCNBH 3 ) converted to a stable amine.
  • the invention further provides the EPO conjugates and EPO conjugate compositions as defined herein for use in the treatment of anemia, for example resulting from chronic kidney disease and myelodysplasia, from the treatment of cancer, for example by chemotherapy and/or radiation, and from other critical illnesses, for example heart failure.
  • the EPO conjugates and the pharmaceutical compositions according to the present invention are further intended for use in the treatment of a disorder related to a reduction of red blood cells, particularly for use in the treatment of a disorder related to a reduction of red blood cells, wherein the risk of side effects caused by abnormally high EPO levels is increased.
  • Caco-2 cells were seeded on the tissue-culture-treated polyesters filters (growth area 1.12 cm 2 , membrane pore size 0.4 ⁇ ) in Transwell 12 wells per plates (Costar 3460) at a seeding density of 100,000 cells/well.
  • DMEM SIGMA, D5921 ;
  • Dulbecco's modified Eagle's medium supplemented with 10% HIFBS (heat inactivated fetal bovine serum), 1 % glutamine and 1 % antibiotic-antimycotic solution was used as the culture medium, and added to both the donor and acceptor compartments. The medium was replaced every 48 hours. The cultures were kept in an atmosphere of 95% air and 5% C0 2 at 37 °C. Transport experiments were performed 21 days after the seeding.
  • HIFBS heat inactivated fetal bovine serum
  • TEER values transepithelial electrical resistance of the Caco-2 cell monolayers were monitored with a Millicell RTM-Electrical Resistance System (Millipore Corp.) connected to a pair of chopstick electrodes.
  • DMEM pre-warmed transport media
  • the cells were incubated for 3 hours with 0.5 ml transport media containing testing formulation.
  • ELISA protein analysis
  • the TEER value which is a good indicator of Caco-2 cell monolayer integrity, was measured before and after the transport experiment (3h), and also after 24h in the culture media to study the reversibility of the effect of testing formulations on Caco-2 cell monolayer.
  • the apparent permeability coefficient, P app (cm/s) was calculated according to the equation (Eq.1 ):
  • Equation 1 (dQ/dt) is the amount of compound transported within a given time period, A is the surface area of the insert; C 0 is the initial concentration compound on the donor side.
  • Permeability coefficient was calculated only for those testing molecules where TEER value of cells was not affected or showed a gradual recovery over time to the initial TEER value.
  • Rat jejunum was obtained from female Wistar rats. All animals were starved for 18 h before the experiments.
  • the small intestine was immediately excised and placed into the ice-cold bubbled (carbogen, 95:5 0 2 /C0 2 ) 10 mM solution of D-glucose in standard Ringer buffer containing (in mM): 140.6 Na + , 5 K + , 1.2 Ca 2+ , 1 .2 Mg 2+ , 121 .8 CI " , 25 HC0 3 " , 0.4 H 2 P0 4 " , 1.6 HP0 4 2" . Jejunum was used in the experiments. The tissue was cut into 3 cm long segments, excluding visible Peyer's patches.
  • the intestinal segments were opened along the mesenteric border, stretched onto a special insert followed by the gentle removal of serosa and layers of muscularis externa to facilitate erythropoietin detection in the acceptor chamber.
  • the intestinal segments were then placed between the two EasyMount side-by-side diffusion chambers with the exposed tissue area of 1 cm 2 (Physiologic Instruments, San Diego, CA, USA).
  • the intestinal segments were bathed with standard Ringer buffer (pH 7.0 donor chamber and pH 7.4 acceptor chamber) supplemented with 10 mM mannitol on the mucosal side and with 10 mM D-glucose on the serosal side.
  • protease inhibitors cocktail (Sigma) was added to the acceptor and the donor chamber and 1 % m/v of bovine serum albumin was added to acceptor chamber only.
  • the bathing solution was continuously gassed with carbogen gas (95:5 0 2 /C0 2 ) and kept at 37°C.
  • the testing formulations were added to the mucosal side to study the mucosal-to-serosal (MS) transport of erythropoietin.
  • the final volume of the solution in each compartment was 2.5 ml.
  • Samples of 250 ⁇ were withdrawn from the acceptor and from the donor compartment at 30 min and 90 min intervals, respectively, up to 180 min and replaced with fresh Ringer buffer containing 10 mM D-glucose (acceptor) or 10 mM mannitol (donor) to maintain a constant volume. Samples were put on -80°C immediately after sampling and were then analyzed (ELISA). Obtained data were analyzed according to the Equation 1.
  • the diffusion chambers were equipped with two pairs of Ag/AgCI electrodes for measuring trans- epithelial potential difference (PD).
  • the experiments were performed under the open circuited conditions.
  • the tissue viability and integrity was continuously checked by monitoring PD and (TEER) and additionally by recording the PD after the addition of D-glucose (25 mM) to the mucosal compartment at the end of the experiments.
  • the permeability coefficient was calculated only for those formulations where experimental tissue was viable throughout the experiment as observed by the tissue response in PD parameter after the addition of D-glucose.
  • test items were administered subcutaneously only once (at day 0 of the study) and blood samples were taken every second day throughout the 24 day lasting study.
  • Blood samples were collected from the terminal vein (40 ⁇ ) into the pipette and immediately diluted with Cellpack reagent, Sysmex (160 ⁇ , 1/5, v/v) in 0.5 ml Eppendorf tubes.
  • Hematological parameters were evaluated with the hematological analyzer Sysmex XT-2000iV according to the Sysmex manufacturer's instructions. The most important parameter, reticulocytes, was compared between formulations administered. Body weight and clinical signs were also observed before and after the application and daily during experiment. At the end of the experiments, all animals were humanly sacrificed under C0 2 and anesthesia. Tissues and organs were macroscopically examined for potential abnormalities.
  • Recombinant human EPO - rhEPO at concentration 2.5 mg/ml (15.6 ml, 1.28 ⁇ ) was used in conjugation reactions.
  • SFB was dissolved in 100% dimethylsulfoxide (DMSO) to a concentration of 2.0 mg/ml. All reactions were performed at pH 7.0 in phosphate buffer (150 mM NaCI, 50 mM Na phosphate) using thirty fold molar excess of the SFB over rhEPO.
  • the conjugate was separated from unreacted rhEPO, SFB and 6-aminocaproic acid by gel filtration on Superdex75 PrepGrade (XK 26/60) column. Elution (4.5 ml/min) was done with phosphate buffer (150 mM NaCI, 50 mM Na phosphate) containing 20 % glycerol. Fractions containing product were collected, concentrated and sterile filtrated. Purified EPO derivative, mC6EPO, was additionally analyzed by SDS-PAGE and RP-HPLC. Permeability of mC6EPO on Caco-2 cell monolayer
  • Table 2 Compositions of testing formulations of mC6EPO with PMAL (PMAL-C10, [Poly (maleic anhydride-alt-1-dodecene) substituted with 3-(Dimethylamino) propylamine]) and CYMAL (CYMAL-7, 7-cyclohexyl-1-heptyl-maltoside), respectively, TEER value after 3h of treatment and 24h after the experiment, and calculated permeability for mC6EPO. Enhancement ratio (ER) of P ap p is also presented.
  • NP Nanoparticles
  • CS chitosan
  • TMC trimethylchitosan
  • tpp Trimethylchitosan
  • Table 3 Composition of testing formulations: EPO (0.3 mg/ml) and mC6EPO (0.3 mg/ml) in formulation with PMAL-C10 (1.0 mg/ml), tissue viability after 4h of experiment, and calculated permeability for EPO and mC6EPO with PMAL (ditto). Factor of relative P app increase for formulation is also presented.
  • Recombinant human EPO - rhEPO at concentration 2.5 mg/ml (15.6 ml, 1.28 ⁇ ) was used in conjugation reaction.
  • SFB was dissolved in 100% dimethylsulfoxide (DMSO) to concentration 2.0 mg/ml. All reactions were performed at pH 7.0 in phosphate buffer (150 mM NaCI, 50 mM Na phosphate) using thirty fold molar excess of the SFB over rhEPO.
  • the concentration of DMSO in protein reaction mixture was 3.5 %.
  • the reaction mixture was stirred slowly at 60 rpm for 16 hours at 20 °C.
  • the conjugate was separated from unreacted rhEPO, SFB and 8-aminocaprylic acid by gel filtration on Superdex75 PrepGrade (XK 26/60) column. Elution (4.5 ml/min) was done with phosphate buffer (150 mM NaCI, 50 mM Na phosphate) containing 20 % glycerol. Fractions containing product were collected, concentrated and sterile filtrated. Purified EPO derivative, mC8EPO, was additionally analyzed by SDS-PAGE and RP-HPLC.
  • EXAMPLE 3 Hematological parameters in rats after single subcutaneous administration of EPO and its derivative mC6-EPO ⁇ in vivo experiment)
  • Samples presented in Table 5 were administered subcutaneously (s.c) to rats at EPO or mC6EPO doses of 4 ⁇ g/kg .
  • the volume of administration per rat was approximately 0.1 ml. Table 5.
  • the most important hematologic parameter - reticulocytes - was monitored every second day throughout the 24 day lasting study. In both s.c. groups, receiving EPO or mC6EPO respectively, the increase of reticulocytes is prominent on day 4 after application. The statistical tests confirmed the statistically relevant increase on this day in comparison to day 0. The peak is higher in EPO group; however, the group receiving derivative mC6EPO showed similar profile retaining 80 % of EPO biological activity. At the end of the study, after rats were humanly sacrificed, all organs and tissue (including gastrointestinal tract) were macroscopically observed and showed no abnormalities.
  • EPO derivative mC6EPO has in vivo biological activity of causing bone marrow cells to increase production of reticulocytes and red blood cells.
  • surface modification of the EPO it was not predictable that the increase in reticulocytes formation was not more impaired, or that a relative activity of 80 % of reticulocytes formation, in respect of unmodified EPO, was maintained.
  • Recombinant human EPO - rhEPO at concentration 2.0 mg/ml was incubated for 30 min in the presence of 10 mM sodium periodate at room temperature. Oxidation reaction was stopped by addition of glycerol. Next 60 fold molar excess of hexylamine (or 6-amino caproic acid in the case of preparation of glycol-caproic EPO conjugate) was added to the solution and incubated for several hours at room temperature in the presence of 20 mM NaCNBH3.
  • the conjugate was separated from reactants by gel filtration on Superdex200 PrepGrade (XK 26/60) column. Elution at flow rate 4.5 ml/min was done in phosphate buffer (150 mM NaCI, 50 mM Na phosphate) containing 20 % glycerol. Product containing fractions were collected, concentrated and sterile filtrated. Purified conjugates were analyzed by SDS-PAGE, RP-HPLC and DEAE.
  • Glyco-hexyl EPO and Glyco-caproic EPO conjugates exhibit enhanced permeability across the cell monolayer.
  • glycol-caproic EPO conjugate showed significant increase in Papp as enhancement ratio was up to 60 in comparison to unmodified protein.
  • Yung adult Winstar rats (Harlan) were used in experiments, each test group containing 6 animals.
  • Placebo and test items were administered once, i.e. on day 0.
  • Eppendorf 0.5 mL tubes which were suitably labeled. Some blood samples were measured twice to check the uniformity of measurements. The following parameters were evaluated according to the Sysmex manufacturer's instructions and to the SOP (ND_Gen200609) in all animals:
  • Test items were prepared as freeze-dried products which were rehydrated in water before the application and prepared as a final dispersion for oral application.
  • Test item 1 labeled Lio- mC6EPO-B"' contained nanoparticles composed of mC6EPO, CYMAL7, and
  • Lio-mC6EPO-D contained nanoparticles composed of mC6EPO, CYMAL7, and chitosan/tripolyphosphate. Initial loading of mC6EPO was 15% and 1.5x mass excess of CYMAL7 relative to mC6EPO was used. In group 3 (Placebo group) animals received demi water given by gavage.
  • the most responsive hematological parameter was the number of reticulocytes determined at individual time points in the blood samples. Response curves were generated by plotting Reticulocyte count (in number) against time for individual animal in the test group. Individual response was evaluated by calculating AUC (area under the curve) taking zero time point and day six time point as a baseline values.
  • Bioavailability (BA) of per-orally administered mC6EPO formulations was calculated relative to the average AUC values obtained in the same way as described before for subcutaneously administered mC6EPO conjugates (study P44) using the equation:
  • Bioavailability (BA) of mC6EPO formulations calculated was up to 1 % in individual animal after peroral application.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des conjugués d'érythropoïétine (EPO) présentant une biodisponibilité et une efficacité élevées, en particulier lorsqu'ils sont administrés par voie pérorale. L'invention concerne également des procédés de préparation des conjugués d'EPO, leur utilisation pour le traitement de diverses maladies, et des compositions pharmaceutiques comprenant les conjugués d'EPO, seuls ou en combinaison avec des séquences activatrices d'absorption et/ou des polymères de revêtement.
PCT/EP2014/069198 2013-09-09 2014-09-09 Conjugués d'érythropoïétine présentant une biodisponibilité orale Ceased WO2015032981A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13183610.8 2013-09-09
EP13183610 2013-09-09

Publications (1)

Publication Number Publication Date
WO2015032981A1 true WO2015032981A1 (fr) 2015-03-12

Family

ID=49117757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/069198 Ceased WO2015032981A1 (fr) 2013-09-09 2014-09-09 Conjugués d'érythropoïétine présentant une biodisponibilité orale

Country Status (1)

Country Link
WO (1) WO2015032981A1 (fr)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108667A2 (fr) * 2003-05-30 2004-12-16 Centocor, Inc. Formation de nouveaux conjugues d'erythropoietine au moyen d'une transglutaminase
WO2005065239A2 (fr) * 2003-12-31 2005-07-21 Centocor, Inc. Nouvelles proteines recombinees avec thiol libre n-terminal
US20070237827A1 (en) * 2005-01-04 2007-10-11 Hsing-Wen Sung Nanoparticles for drug delivery
WO2008008363A1 (fr) * 2006-07-11 2008-01-17 Qps, Llc Compositions pharmaceutiques pour délivrance à libération prolongée de peptides
WO2010075465A1 (fr) * 2008-12-22 2010-07-01 Aegis Therapeutics, Llc Compositions pour administration de médicaments
US20130224213A1 (en) * 2010-06-24 2013-08-29 Genetech, Inc. Compositions and Methods for Stabilizing Protein-Containing Formulations

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004108667A2 (fr) * 2003-05-30 2004-12-16 Centocor, Inc. Formation de nouveaux conjugues d'erythropoietine au moyen d'une transglutaminase
WO2005065239A2 (fr) * 2003-12-31 2005-07-21 Centocor, Inc. Nouvelles proteines recombinees avec thiol libre n-terminal
US20070237827A1 (en) * 2005-01-04 2007-10-11 Hsing-Wen Sung Nanoparticles for drug delivery
WO2008008363A1 (fr) * 2006-07-11 2008-01-17 Qps, Llc Compositions pharmaceutiques pour délivrance à libération prolongée de peptides
WO2010075465A1 (fr) * 2008-12-22 2010-07-01 Aegis Therapeutics, Llc Compositions pour administration de médicaments
US20130224213A1 (en) * 2010-06-24 2013-08-29 Genetech, Inc. Compositions and Methods for Stabilizing Protein-Containing Formulations

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BONNIE M. GORZELLE ET AL: "Amphipols Can Support the Activity of a Membrane Enzyme", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 124, no. 39, 1 October 2002 (2002-10-01), pages 11594 - 11595, XP055093761, ISSN: 0002-7863, DOI: 10.1021/ja027051b *
VENKATESAN N ET AL: "Pharmacokinetic and pharmacodynamic studies following oral administration of erythropoietin mucoadhesive tablets to beagle dogs", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER BV, NL, vol. 310, no. 1-2, 9 March 2006 (2006-03-09), pages 46 - 52, XP027972720, ISSN: 0378-5173, [retrieved on 20060309] *

Similar Documents

Publication Publication Date Title
JP2980569B2 (ja) インターフェロン複合体
EP2459226B1 (fr) Glyco-polysialylation de protéines autres que des protéines de coagulation du sang
US8003089B2 (en) Y shape branched hydrophilic polymer derivatives, their preparation methods, conjugates of the derivatives and drug molecules, and pharmaceutical compositions comprising the conjugates
EP2258397B1 (fr) Conjugué de polymère et de substance physiologiquement active
EA011829B1 (ru) Полиалкиленгликоль с остатком для конъюгации биологически активного соединения
US20120191039A1 (en) Carrier linked pramipexole prodrugs
JP2022058911A (ja) 非血液凝固タンパク質の糖ポリシアル酸化
WO2007083984A1 (fr) Conjugué comprenant un composé pharmaceutiquement actif lié de façon covalente à un polymère mucoadhésif et méthode d'administration transmucosale de composé pharmaceutiquement actif faisant appel audit conjugué
KR20120073196A (ko) 비혈액 응고 단백질의 글리코폴리시알화
TW200812572A (en) Polymer conjugate of taxane
WO2013067767A1 (fr) Conjugué médicamenteux de polyéthylèneglycol-oligopeptide d'acides aminés-irinotécan et composition médicamenteuse de celui-ci
EA020069B1 (ru) Жидкая лекарственная форма конъюгата
US20030103934A1 (en) Drugs having long-term retention in target tissue
JP2007528347A (ja) 延長された生体内半減期を有するｐｅｇ−生理活性ポリペプチド同種二量体結合体及びその製造方法
RU2488598C2 (ru) Гормон роста, модифицированный двухцепочечным полиэтиленгликолем, способ его получения и применение
CN117599013A (zh) 纳米组合物及其制备方法和用途
CN101367872A (zh) 蛋白质-聚合物缀合物
US7708978B2 (en) Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders
WO2015032981A1 (fr) Conjugués d'érythropoïétine présentant une biodisponibilité orale
BRPI0919827B1 (pt) processos para aumentar o rendimento de uma reação de peguilação de r-methug-csf processo para a produção em escala grama de peg- r-methug-csf
TW201138831A (en) Modified granulocyte colony stimulating factor (G-CSF)
WO2020169004A1 (fr) Conjugué à bras multiples ciblant cd44
WO2015032973A1 (fr) Compositions d'érythropoiétine pour une administration orale
US11524078B2 (en) Water-soluble macromolecular derivative of Venetoclax
CN115887689A (zh) β-葡聚糖与M2巨噬细胞靶向肽偶联物、制备方法及重塑肿瘤微环境和免疫抗肿瘤的应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14771222

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14771222

Country of ref document: EP

Kind code of ref document: A1